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Background: Telehealth services based on at-home monitoring of vital signs and the administration of clinical
questionnaires are being increasingly used to manage chronic disease in the community, but few statistically robust
studies are available in Australia to evaluate a wide range of health and socio-economic outcomes. The objectives
of this study are to use robust statistical methods to research the impact of at home telemonitoring on health care
outcomes, acceptability of telemonitoring to patients, carers and clinicians and to identify workplace cultural factors
and capacity for organisational change management that will impact on large scale national deployment of telehealth
services. Additionally, to develop advanced modelling and data analytics tools to risk stratify patients on a daily basis to
automatically identify exacerbations of their chronic conditions.
Methods/Design: A clinical trial is proposed at five locations in five states and territories along the Eastern Seaboard of
Australia. Each site will have 25 Test patients and 50 case matched control patients. All participants will be selected
based on clinical criteria of at least two hospitalisations in the previous year or four or more admissions over the last
five years for a range of one or more chronic conditions. Control patients are matched according to age, sex, major
diagnosis and their Socio-Economic Indexes for Areas (SEIFA). The Trial Design is an Intervention control study based
on the Before-After-Control-Impact (BACI) design.
Discussion: Our preliminary data indicates that most outcome variables before and after the intervention are not
stationary, and accordingly we model this behaviour using linear mixed-effects (lme) models which can flexibly model
within-group correlation often present in longitudinal data with repeated measures. We expect reduced incidence of
unscheduled hospitalisation as well as improvement in the management of chronically ill patients, leading to better
and more cost effective care. Advanced data analytics together with clinical decision support will allow telehealth to be
deployed in very large numbers nationally without placing an excessive workload on the monitoring facility or the
patient's own clinicians.
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In industrialized nations approximately 70-78% of health-
care budgets are spent on the management of chronic
disease or its exacerbation [1-3] and as the population
ages the burden of chronic disease increases and places
healthcare budgets under increasing strain.
A strong primary health care system has been acknowl-
edged as critical to the sustainability of health care systems
both in developing and industrialised nations and it has
emerged as a recurrent theme in recent years [4-6]. The
management of chronic disease, much of which could
occur in home and community settings, often unnecessarily
burdens hospital-centric public health system. As a conse-
quence policy makers and health service managers seek in-
novations that deliver the same or improved health services
using proportionately fewer resources.
Telehealth services have been demonstrated inter-
nationally to be one such innovation [7,8], but there are
low levels of evidence from Australian studies [9]. This
study will evaluate whether the introduction of in-home
telemonitoring services to the management of chronic
disease in the community reduces patient use of the
health system and improves healthcare outcomes and
their quality of life.
We will also explore the extent to which real-time risk
stratification of these patients is of value to health pro-
fessionals and the issues and challenges in deploying
telemonitoring services in the community.
Telehealth and telecare technologies and services for
the management of chronic disease at home and in the
community have been of intense interest in developed
western economies because of unprecedented growth
rates of the aged population and increasing morbidity as
population ages. These factors place unsustainable stress
on established health care services, and will result in
increasing deficits in clinical human resources, expand-
ing disease management programs and patient demand
for greater self-management.
Telehealth services, delivered through home tele-
monitoring, have been demonstrated to deliver cost
effective, timely and improved access to quality care
[7,9-12]. They also reduce social dislocation and en-
hance the quality of life and the sustainability of these
communities by allowing chronically ill and aged mem-
bers to stay in their homes and communities longer.
However experience in Australia with the deployment
of Telehealth services is extremely limited [13], with
most deployments of small scale and lacking detailed
analysis of key success factors such as:
 Health care outcomes
 Health economic benefits
 Impact on clinical work force availability and
deployment Human factors (acceptability, usability by patients,
carers, nurses, GPs and administrators)
 Workplace culture
 Capacity for organisational change management and
business processes
The development of a robust business case and business
models for large scale commercial deployment of Tele-
health services, based on reliable socio-economic evidence,
is therefore essential if these services are to be deployed
nationally to mitigate the escalating costs of health service
delivery and the increasing deficit in clinical work force.
This trial will seeks to create a robust evidence base
for these key success factors and demonstrate an effect-
ive and scalable model for an internet-enabled Tele-
health services in Australia. Armed with the insights
provided by this evidence base, policy makers may have
much of the data they require to implement funding
models and create a sustainable Telehealth services sec-
tor in Australia.
Despite large national investments in health IT, very
little policy work has been undertaken in Australia in
deploying Telehealth in the home as a solution to the
increasing demands and costs of managing chronic
disease. In contrast in the UK, the first report from the
Department of Health (DH) on this subject was pub-
lished in 2000 [14] and many others have followed since
[15-17]. The DH’s Preventative Technology Grant (PTG)
from 2006–08 provided £80 M to local authorities and
their partners for investment in assistive technology [18]
and most recently £31 m of funding for a Whole System
Demonstrator (WSD) program which had Telehealth as
an integral part for the management of long-term condi-
tions [11,19].
The Litan report [7] provides a comprehensive re-
view of the international evidence that Telehealth
services for the management of chronic disease can re-
duce admission to Accident and Emergency (A&E)
from between 20-60%. In one report quoted, Strategic
Healthcare Programs, LLC (2004), Physiological moni-
toring of Heart and lung disease and diabetes reduced
A&E visits by 49% for Congestive Heart Failure (CHF)
patients, 66% for Chronic Obstructive Pulmonary Dis-
ease (COPD) patients, and 83% for diabetes patients.
Most recently the Whole System Demonstrator [11]
Headline Findings released by the UK Department of
Health in December 2011, demonstrated;
 15% reduction in A&E Visits
 20% reduction in emergency admissions
 14% reduction in elective admissions
 14% reduction in bed days
 8% reduction in tariff costs and
 45% reduction in mortality rates
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health and telecare in the world, involving 6191 patients
and 238 GP practices across three sites, Newham, Kent
and Cornwall. Three thousand and thirty people with
one of three conditions (diabetes, heart failure and
COPD) were included in the telehealth trial [19].
The most large scale example of Telehealth use is in
the US by the Veterans Health Administration (VHA).
VHA mainstreams clinical care within its Coordinated
Care and Home Telehealth (CCHT) project [12]. Routine
analysis of data obtained for quality and performance
purposes from a cohort of 17,025 CCHT patients
shows the benefits of a 25% reduction in numbers of
bed days of care, 19% reduction in numbers of hospital
admissions, and mean satisfaction score rating of 86%
after enrolment into the program. VHA’s experience is
that an enterprise-wide home telehealth implementa-
tion is an appropriate and cost-effective way of man-
aging chronic care patients in both urban and rural
settings.
Most recently [20] the US Department of Veterans
Affairs announced that 690,000 US veterans received
care in the 2014 fiscal year via telehealth, with 2 million
telehealth visits scheduled. That means that 12 percent
of all veterans enrolled in VA programs received tele-
health care of some kind in 2014.
Aims and objectives
This study was designed with the aim of demonstrating
how telehealth services for chronic disease management
in the community can be deployed nationally in Australia
in a range of hospital and community settings and to
develop advanced modelling and data analytics tools to
risk stratify patients on a daily basis to automatically
identify exacerbations of their chronic conditions.
The following research questions will be addressed;
 Effect of telemonitoring on health service utilisation
– Unscheduled visits to hospital, visits to GPs and
Nurse visits
– Cost and frequency of consultations, laboratory
tests and other clinical procedures
 Effect of telemonitoring on patients outcomes
– Quality of life, progression of chronic condition,
wellbeing, medication adherence
 Service implementation and deployment
– Existing model of care, service design, adoption
and appropriation
 User experience and service implementation
– Satisfaction, useability, acceptance, workload,
anxiety and strain among study participants
including health professionals, administrators,
patients and carers
 Service implementation issues– How the new home monitoring service is
implemented at each site. What impact has this
had on the process and outcomes of normal care
delivery?
– How are existing service practices evolving as a
result of the new service?
– What can be learnt from different
implementation approaches?
 Cost effectiveness analysis
– Analysis of reductions/increases in costs borne by
patients as a result of telehealth
– Analysis of reductions/increases in costs borne by
the commonwealth and on-the-ground service
providers for patients as a result of the deploy-
ment of telehealth services
The Project Objectives are to:
 Demonstrate and document how telehealth services
can be successfully deployed across Australia, by
piloting services in five different settings across five
states with a range of health service provider’s,
including Local Health Districts, Medicare Locals
and not for profit community organisations. This
will be demonstrated by deploying and
demonstrating the operation of Telehealth
monitoring in a multi-site multi-state case matched
control trial (Before-After-Control-Impact (BACI)
design) of chronically ill patients living in their own
homes in the community. This has never previously
been attempted in Australia.
 Provide the clinical and health economic evidence on
how Telehealth services can be scaled up nationally to
provide an alternative cost effective health service for
the management of chronic disease in the community.
 Provide evidence that at home telemonitoring has
the potential to reduce unscheduled admissions to
Accident and Emergency (A&E) compared to the
control group.
 Provide evidence for an impact on hospital
admissions, mortality, clinical events and symptoms
and improvements in functional measures and
patients' and carers’ experiences with care.
 Evaluate health economic benefits
 Evaluate impact on clinical work force availability
and deployment
 Evaluate impact of human factors (acceptability,
usability by patients, carers, nurses, GPs and
administrators, impact on workplace culture)
 Evaluate impact of workplace culture
 Evaluate impact of organisational change
management and business processes
 Develop a new evidence based data analytical
technique for the risk stratification of patients’
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facilitates the management of large numbers of
patients by orchestrating an optimal and timely
allocation of resources to avoid unnecessary
hospitalisation
For each of the above objectives, operation of the trial
at five different sites representing a range of different
models for the management of chronic disease in the
community will allow the identification and analysis of
site specific differences in workplace culture, organisa-
tional change management and staff and management
capabilities that contribute to differences in measured
health, social and economic outcomes.
Methods/Design
Immediately following granting of funds for the project in
December 2013, Ethics Approval was sought and granted
by the CSIRO CAFHS Human Research Ethics Commit-
tee, on the 25th March 2013 (approval # 13/04). Subse-
quently, ethics approval was also obtained from health
authorities at each of the test sites as well as from the
Commonwealth Department of Health and Ageing and
the Department of Human Services. The latter two were
necessary in order to be granted access to national patient
data stored in the Medicare MBS and PBS archives.Figure 1 Trial sites along Eastern seaboard of Australia and in TasmaThe trial sites are located over widely dispersed re-
gions of the Eastern Seaboard of Australia as shown in
Figure 1. They were selected on the basis of three
criteria, (i) early participation in the rollout of the
National Broadband Network, (ii) geographical loca-
tion and demographics and (iii) variations in models of
care used to manage Chronic disease to be generally
representative of the variety of models of care for the
management of chronic disease existing in Australia.
Organisation and management
Establishing an appropriate Governance model for man-
aging such a complex project is critical in order to com-
ply with the requirements of the National Statement on
Ethical Conduct in Human Research (2007) [21], the
specific requirements of multiple Human Research
Ethics Committees and the statutory requirements of
the Therapeutic Goods Administration regarding the
use of medical devices for monitoring health status.
The Organisational structure shown below in Figure 2
was established in April 2013. Clinical groups meet on a
weekly basis and are chaired by the Project Manager or
the Clinical Trial Coordinator. The four research teams
also meet weekly to monitor progress against project
milestones. The Project Management Committee meets
monthly to monitor and review progress of the projectFrom North to South,
• Townsville (Queensland)
• Penrith (NSW)
• Nepean Blue Mountains 
Local Health District (NSW)*
• Canberra (ACT) 
• Ballarat (Victoria) 
• Launceston (Tasmania)
*The Penrith and Nepean Blue  
Mountains sites were subsequently 

















































Figure 2 Project organisation and management structure. CTC – Clinical Trial Coordinator. PO –Project Officer and CCC – Clinical Care
Coordinator at each trial site.
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Committee is Chaired by the Project Director and in-
cludes representatives from each site as well as two cli-
nicians, one representing the interests of General
Practice and the other, Chairing the Adverse Events
and Death Review committee which meets whenever
necessary.
Selection of trial participants
Since random selection of patients was not possible be-
cause of small sample sizes and the initial requirement
that Test patients be selected from areas connected to
the NBN, a Before After Control Intervention (BACI)
design [22] was adopted that foregoes assumptions of
normality. The BACI paired samples design provides
greater control over confounding variables, increases the
power of the study and improves the chances of finding
a significant result with a smaller number of samples if
the impact is relatively small.
The research protocol requires the recruitment of 75
participants at each of the five sites to achieve a total
sample size of 375. Of these 125 are Test patients and
250 are Control patients. At each site 25 participants are
allocated to the intervention, with 50 remaining control
participants receiving normal care as per their site’s
existing model of care.
Eligible candidates are identified primarily by search-
ing the local hospital patient administration system
(PAS) for patients who satisfy the eligibility criteria de-
scribed in Table 1. Some candidates were also identified
by site clinical staff familiar with their medical history.Typically between 250 and 300 eligible patients are
identified by searching the hospital records of the
major community hospital in the region. Candidates
are eligible to participate in the study if they meet all
inclusion and none of the exclusion criteria listed in
Table 1 and become participants on the signing of
informed consent in the presence of an independent
witness.
For the purposes of our study unplanned admissions
are all admissions other than:
1. Admissions from the waiting list (including both the
surgical list and the medical waiting list);
2. Admissions listed as "regular same day planned
admissions" which are admissions that are intended
regular and planned same‐day admissions for an
on‐going phase of treatment, such as renal dialysis
or chemotherapy.
Following the signing of a consent form and comple-
tion of the Entry Questionnaire, Test patients are con-
nected to the internet and supplied with the TMC
Telemonitoring system and trained on its use by the
Project Officer (PO) at each site. Their vital signs and
questionnaire responses are subsequently monitored on
a daily basis by the Clinical Care Coordinator (CCC).
On site visits and technical support as well as the
obtaining of Consent and the administration of Exit
questionnaires are the responsibility of the PO.
Control patients also complete the Entry questionnaire
but otherwise continue to receive normal care. For each
Table 1 Clinical criteria for eligibility
Criteria Type Description
Age Inclusion 50 years old and over at consent.
Cognitive capacity Inclusion Abbreviated Mental Test (AMT) [23] score >7.
Unplanned acute admissions Inclusion A rate of unplanned acute admission with the required principal
diagnosis code(s) indicated below:
a) ≥2 in the last 12 months, or
b) ≥4 in the previous 5 years.
ICD-10-AM principal diagnosis code(s) for each unplanned
acute admission
Inclusion Code(s) for each unplanned acute admission indicate a diagnosis
for one or more of the following chronic conditions:
a) Chronic Obstructive Pulmonary Disease (J41 – J44, J47 and J20,
with secondary diagnosis of J41-J44, J47),
b) Coronary Artery Disease (I20 – I25),
c) Hypertensive Diseases (I10 – I15, I11.9. Note: Hypertensive Heart
Failure (I11.0) is included in Congestive Heart Failure),
d) Congestive Heart Failure (I11.0, I50, J81),
e) Diabetes (E10 - E14),
f) Asthma (J45).
Unsuitable conditions Exclusion The study team considers the presence of the following conditions
to be unsuitable for participation in the study:
a) Any form of cancer,
b) Any neuromuscular disease
c) Any psychiatric conditions.
Care team Inclusion The eligible patients must be under the care of any of the following:
a) General Practitioner
b) Community Nurse
Care programs Inclusion Participation in one of the following government care programs:
a) Commonwealth Chronic Disease Management
b) Commonwealth Coordinated Veterans’ Care Program
c) NSW Connected Care Program
Unsuitable care programs Exclusion Participation in one of the following government care programs:
a) Commonwealth Extended Aged Care in the Home
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dates are automatically case matched on gender, age,
chronic condition and Socio-Economic Indexes for Areas
(SEIFA) [24]. On their consent the two closest matching
control candidates commence as participants in the study.
The remaining four candidates are held in reserve. Table 2
below demonstrates the case matching process.
Generally, the closer the match the greater the likeli-
hood of finding a significant result with a smaller num-
ber of samples if the impact is relatively small.
Ideally, as many as four matches are sought for each
Test patient, and the closest match is then selected as
the case matched control for that Test patient. In many
cases only one acceptable match may be available.
Following a change of Government in Australia, the
requirement to connect patients to the high speed
National Broadband Network was removed and as con-
sequence, approximately half of our trial patients willbe connected to a variety of NBN, ADSL, ADSL2 and
VDSL network services with a minimum level of ser-
vice of 2Mbps download and 1Mbps upload. Those on
the NBN service were guaranteed a download speed of
25Mbit/sec and an upload speed of 5Mbit/sec.
Subject enrollment and consent
Eligible patients are initially contacted by the Trial PO
and given a detailed information sheet outlining the
project. Confirmation of willingness to participate is via
a consent document witnessed by a person independent
of the project. Upon consenting the patient is adminis-
tered a comprehensive Point of Entry Questionnaire
as described in Table 3 using OpenClinica [25], the
world's first commercial open source clinical trial soft-
ware for Electronic Data Capture (EDC) and Clinical
Data Management (CDM), as the data depository and
data management system. Processes are then put in
Table 2 Example of case matching of Control patients with Test patients
Test/control Age Gender Major diagnosis Seifa1 index for postcode Strength of match (perfect match = 0)
Test 54 M COPD 1023
Control 56 M COPD 1025 1.682
Control 54 F HD 1022 2.163
Weights 0.2 1 1 0.16
1SEIFA 2011 Socio-Economic Indexes for Areas [24]. SEIFA provides measures of socio-economic conditions by geographic area.
2|54-56| × 0.2 + 1 × 0 + 1 × 0 + |1023-1015| × 0.16 = 1.68.
3|54-54| × 0.2 + 1 × 1 + 1 × 1 + |1023-1022| × 0.16 = 2.16.
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the patient on its use. A Quality Control process operates
for one week to ensure that patient training is adequate
and the quality of the data recorded is acceptable.
Once each Test patient is consented, an automated case
matching process is carried out as already described.
Selection of Tele-monitoring service provider
CSIRO undertook a comprehensive and independent
Technology Assessment process to select the telehealth
service provider for this project. The selection commit-
tee was chaired by the Leader of the Health Services
Theme, and comprised six members including partner
representatives.
From an initial review of companies operating in the
Australia market, six were selected for further consi-
deration based on length of presence in Australia and
experience with supporting telehealth services in a trial
environment. These were requested to provide detailed
information on their at home tele-monitoring equipment
and ultimately three were interviewed and asked to
provide a physical demonstration of their equipment.
Criteria for selection included the following;
Range of vital signs measurements available, patient
Video conferencing and messaging capability, Clinical
Questionnaires specific to patient condition, ability to
view vital signs data in raw signal form, quality/ease of
use of patient user interfaces, quality/ease of use ofTable 3 Key elements of the Entry and Exit
Questionnaires
Section Source/questionnaire
1-3 CSIRO Standard Screening Medical Questionnaire
[29] + additional trial specific questions
Selected questions from Living with Diabetes Study [30]
Selected questions from Fat and Fibre Barometer [31]
4 Active Australia [32]
5 Kessler 10 [33]
6 Dimensions from HeiQ (Living with and managing
medical conditions) [34]
7 EuroQol EQ-5D [35]
8 Dimensions from HeiQ (Social Isolation) [34]
9 Morisky Medication Adherence [36]clinician user interfaces, expert system for daily patient
risk profiling, high quality video for delivery of Educa-
tional/training material, multi language capability, qual-
ity standard and data accessibility, regulatory
compliance (TGA, CE Mark, FDA, ISO13485), capabil-
ity to export data from the system, opportunity to part-
ner with the provider to trial new tools, algorithms and
analytic results within their system, evidence of cap-
ability to deploy and service equipment in the field, in-
cluding patient training, remote maintenance etc.,
availability of local R&D support, quality of support
staff and management, evidence of experience in
deploying telehealth services, cost of Equipment/Ser-
vices and data storage location.
Based on a comparative analysis of the criteria identified
above, Telemedcare Systems Pty Ltd [26] was selected as
the telehealth service. Critical attributes identified were
(i) meeting all TGA, FDA and CE Marking regulatory
requirements, (ii) commercial presence in Australia
since 2006 and proven track record in supporting
telehealth projects in Australia and the UK, (iii) Local
customer support and software and hardware R&D
capability, (iv) advanced clinical capability including
spirometry, ecg and auscultatory NIBP and strong local
R&D support and (v) ability to view all recorded traces
for purposes of improved diagnosis and quality control
particularly in patients who may have cardiac arrhythmia.
The TMC Clinical Monitoring Unit (CMU) is shown in
Figure 3. Not all features were necessarily used in this trial.
Data architecture
This study has complex data management and organ-
isational requirements by virtue of its operation in five
different location in five different states and territories,
each with their own Ethics requirements and with dif-
ferent hospital systems from which to source hospital
data. In this section we describe a secure and effective
service-oriented approach for securely managing Tele-
health services research data.
The data architecture and data integration services
developed as part of this project make a considerable
contribution to research and being in the public do-
main, warrant closer examination. A more detailed
description has been published previously [27].
Figure 3 Telemedcare Clinical Monitoring Unit (CMU).
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ent sources, in multiple formats and with varying levels
of automation, with some requiring considerable manual
processing. A simplified diagram of data sources used in
this study is shown schematically in Figure 4 below.
 Entry and Exit Questionnaires are administered on
line by PO’s when Test and Control patients are
consented and are stored in OpenClinica
 Periodic Questionnaires (daily, weekly or monthly)
are scheduled on the TMC clinician website and are
presented and administered directly on the patient
telemonitoring system. The results are stored in the
TMC servers.Figure 4 Schematic diagram of different data sources and their secure i Patient vital signs are recorded as longitudinal
records and original waveforms are recorded and
stored in the TMC server for quality control and
diagnostic purposes. All records are accessible to the
clinicians via the TMC clinician portal.
 Hospital Data is sourced from the Patient
Administration Systems of hospitals servicing the
trial sites and is supplied in the format of the
Hospital Roundtable [28]. This comprehensive data
set is requested for four years prior to enrolment
and for the duration of the trial.
 MBS Data available from the Department of Human
Services following Ethics Approval. This provides a
comprehensive record of all primary care servicesntegration.
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scheme
 PBS Data available from the Department of Human
Services following Ethics Approval. This provides a
comprehensive record of all medications dispensed
under the national health insurance scheme. MBS
and PBS Data is available for a total of 4.5 years
prior to and including the duration of the trial.
 HIE Data from focus groups and structured
interviews are transcribed and annotated before
storage in OpenClinica.
Technical details on the data architecture designed to
provide secure Role Based Access Control to de-identified
patients data for research and analysis has been previously
reported [27].
Questionnaire instruments
A number of questionnaire instruments were developed
or adapted from the literature for use in the trial. All
Patients enrolled in the study were required to take an
Entry and Exit Questionnaire. This questionnaire in-
strument was developed from a base CSIRO CAFHS
Human Research Ethics Standard Screening Medical
Questionnaire [29] with the addition of other question-
naire instruments either wholly or in part, measuring
demographic, lifestyle, health and disease characteris-
tics. Key elements of the Entry and Exit Questionnaires
are described in Table 3 below.
In addition to the Entry questionnaire, a number of
questionnaires are scheduled and administered during
the trial with varying frequency. These are described in
Table 4 below.
Data models
As described earlier, patient data is obtained from mul-
tiple sources and integrated into a single unified data-
base linked via the unique OpenClinica ID (OCID). A
Data Model has been developed which provides the
template for data analysis by linking outcomes and
objectives to specific data variables and identifying the
data sources. This data model underpins nearly allTable 4 Questionnaire Instruments and their schedule
Questionnaire Administering
schedule
COPD (Developed by the Austin Hospital) Daily
CHF (Developed by the Austin Hospital) Daily
EQ-5D (Quality of life)] Weekly
Kessler 10 (Mental health) Monthly
heiQ – selected domains (Self monitoring,
Health services navigation and Social isolation)
Entry, 6 months, Exit
Morisky medicine adherence scale Entry, 6 months, Exitquantitative analysis presented in this report. The data
model is presented below in Table 5.
Data analysis
Data will be analysed using a range of conventional stat-
istical methods used in bio-statistics as well as model
based methods more commonly found in the scientific
statistical literature.
The independent samples t-test is commonly used
when two separate sets of independent, randomly se-
lected and normally distributed samples are available,
one from each of the two populations being compared.
However as explained previously, our project design
makes random selection of Test and Control patients
impossible and the alternative Before and After Control
Intervention (BACI) design was adopted [22]. This
design involved the site PO selecting the test patient
first and then selecting from the remaining eligible test
patients the controls that best match each test patient
in turn.
As a consequence statistical comparisons in this study
can only be validly made on Test – Control matched
pairs and tested using the paired samples or repeated
measures t-tests. We expect to obtain data from 125 test
patients and up to 250 control patients. When two or
more matched Control patients are available their data is
averaged.
Data will be routinely tested for normality and if not
normal, the appropriate transform, often log functions,
will be applied to normalise the data prior to applying
paired samples or repeated measures t-tests. Baseline
characteristics will be described for time intervals as
mean ± SDs for continuous symmetrical variables and
means and 95% Confidence Intervals (CI) for skewed
data. When before intervention data are available on
outcomes, then the differences between the test and
their controls will be tested to examine if there are any
differences in the before intervention period. This
process will be examined visually by examining boxplots
of the time stamped differences (e.g., differences between
the respective monthly variables eg. hospital costs) between
test and control patient outcome measures.
As is common in the life sciences our data may be log-
normal when not zero and may contain numerous zero
values. In these circumstances the data will be modelled
using a lognormal distribution for positive values, to-
gether with an additional probability mass at zero. This
type of distribution is commonly referred to as delta-
lognormal. 95% Confidence limits are calculated accord-
ing to the method of Zou, Taleban and Huo [37].
All statistical tests for the before intervention period
will be two-sided but all tests of whether the interven-
tion made a difference will involve a one-tailed matched
pair t-test, and either a p value of 0.05 or less will be
Table 5 Data Model for evaluating outcomes and objectives
Objective/outcome Data variable Data source
Define the study cohort/confirmation of
selection critera and exclusions
Admitted to hospital for their condition
at least twice in the previous year, or≥
4 times in previous five years
Hospital health roundtable records - obtained
from local hospital for previous five years.
• Date admitted
Exclusions are mental health and
cancer patients
• Date discharged
• Reason for admission (ICD 9/10 Codes)
• Procedures carried out
Establish if telehealth Number of unscheduled admissions to
hospital for their condition





• Reason for admission (ICD 9/10 Classification)
• Medication administered
• Procedures carried out
Establish If telehealth improves patient
outcomes/reduced use of clinical services
(Impact on clinical workforce availability
and deployment)
Number of visits to/by GP MBS records
Number of visits to/by specialists MBS records
Number of visits by community nurse MBS records
Number of visits to/by allied health
(ie occupational therapist)
MBS records (If reimbursable from Medicare)
Changes in prescription history PBS
Communication with CCC CCC Logs from CSIRO Portal
Organisational change management
and impact on workplace culture
Administrative/operational changes
implemented/required in order to
implement the Telehealth service.
Questionnaires and structured interviews.
• Within first three months
• Every six months thereafter
Useability of monitoring equipment Compliance with monitoring schedule,
recorded daily.
TMC Logs






Use of video conferencing TMC Logs
Overall data usage iiNET provided logs
Useability/acceptability Ease of use Questionnaires delivered via TMC
For patients of monitoring Equipment Quality of training received • One month after first deployment
Patient embarrassment if visitors know
they are being monitored
• Midpoint of trial
Acceptability as an item of furniture • At end of trial
Easy or hard to take measurement
Important/not important in patients'
self management
Responsiveness of clinical care
coordinator in responding to changes
Quality of training received
Patient embarrassment if visitors know they
are being monitored?
Easy or hard to take measurement
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Table 5 Data Model for evaluating outcomes and objectives (Continued)
Carers experience with telehealth
(Community nurse/carer)
Ease of use of (i) equipment and (ii) Clinician
website
Questionnaires and structured interviews of
community nurses
Changes to previous clinical models
of care
• One month after first deployment
Effectiveness in improving ability to
deliver care
• Midpoint of trial
Impact on workload • At end of trial
Carer's experience with telehealth
(Relative or other carer)
Effect on carer stress Questionnaires and structured interviews
Effect on carer workload • At first deployment
Effectiveness in improving ability to
deliver care
• Midpoint of trial
Access to clinician web site • At end of trial
Gp experience with telehealth Ease of use Questionnaires and structured interviews of
Patients' GP
Changes to clinical models of care • Within 3 months of first deployment
Effectiveness in improving ability to deliver care • Midpoint of trial
Impact on workload • At end of trial
Useability, acceptability of clinician
web interface
Ease of use? Questionnaires and structured interviews
Quality of training received • One month after first deployment
How many hours required • Midpoint of trial
Value and ease of use of Video
conferencing
• At end of trial
Health economic outcomes Daily cost of hospitalisation Health roundtable data
Cost of procedures carried out whilst
in hospital
Health roundtable data
Cost of visits to/by GP MBS Data
Cost of visits to/by Allied Health
(ie Chiropodist or OT)
MBS Data
Cost of visits by community
Nurse/carer
MBS Data
Cost of travel to GP MBS Data
Loss of earnings if patient is still
employed, from days taken off for
illness or visits to health professionals
Use Google Maps to determine distance
travelled from home address to address of
service location, then apply standard costing
model. Ie flag fall + km charge.
Estimate from patient salary and time spent
on each visit
Cost of delivering telehealth services Cost of clinical care coordinator(s) Health service provider and logs recorded
Cost of clinical nurses/carers Health service provider and logs recorded
Cost of providing network services iiNET billing at commercial rates
Cost of providing Telehealth monitoring
services
TMC commercial daily subscription costs
Depreciated costs of capital equipment Our own project records
Estimate of cost of space for monitoring
centre at each site
Estimates from Health service Provider
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interval will be provided to judge the impact of the
intervention. Statistical analysis will be performed using
Stata Release V.12 (TX: StataCorp LP), SPSS 17, R pack-
age [38] and Microsoft Excel.Classical BACI designs and extensions
Because of the temporal nature of health data and the
underlying trends caused by the increasing burden of
chronic disease with increasing age, before and after
comparisons can be difficult or inconclusive. In this
Celler et al. BMC Public Health 2014, 14:1270 Page 12 of 16
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4.5 years including the period of the intervention which
may vary from 6–18 months.
Since standard BACI design cannot be used when
study variables trend over time, we adopt a mathemat-
ical approach using a mixed linear effects model (lme)
to assess the intervention while trying to adjust for the
time varying mean in simple ways. The nlme library in
the statistical package R is used to perform the analysis
according to the methods of Pinheiro et al. [39].
The Test patients will be matched with one or two
controls and the relative movement of Test patients’
outcomes before and after the start of the intervention
will be compared to that of their Control patients. The
before-and-after comparisons use control patients to
adjust for background variations in such variables as
public health policy impacting on costs and even for ex-
ample, climatic conditions during the before and after
intervention period.
Let yijk be any of the variables to be analysed, such as
for example, the PBS/MBS/Hospital costs value per
unit time period (month) at time k during period i
(before or after the intervention), for patient j (control
or intervention patient). The model for the response
value is given by
yijk ¼ μþ ai þ τk ið Þ þ βj þ θk þ aβð Þij þ eijk
where:
 μ is the overall mean
 αi is the effect of period (before and after)
 τk(i) is the repeated measures within periods
(assumed to be a random effect)
 βj is the effect on jth matched patients (intervention
or control)
 (αβ)ij is the interaction between period and matched
patient groups
 θ is the overall slope relating to time in months if no
differentiation is made between the groups (B-A, C-I)
 θij is the slope relating to time (k) in months for the
various combinations of the groups (B-A, C-I).
 eijk is the random error term of the model that is
assumed to be normally distributed with
homogeneous variance.
Assumptions made:
 Log of cost plus one will be treated as normally
distributed with log of the number of days in the
month as the offset. Sometimes the square root
transformation may be used to stabilise the
variance. We are hoping there are not too many
zero cost periods or zero counts. If this fails we will
use the zero adjusted inverse Gaussian distributionfor the model – fitting them using the gamlss
(package in R) using random() for including random
effects [40].
 τk(i) is a random effect in the above model that is
assumed to be normally distributed with mean zero
and constant variance.
 The assumption in the previous dot point and the
assumption for eijk in the model thus assumes that
measurements made at the same time segments
(e.g., on the same quarter) have the same correlation
and homogeneous variances for all repeated
measures.
 The above model treats the study as a fully-designed
experiment with the appropriate randomisation.
However, this is seldom the case because most
impact studies are observational in nature.
 The assumption is that each measurement for the
intervention patients is matched with a measurement
for one or more control patients. This blocking is
expected to control for the non-randomisation in the
design. The complexity of this analysis can be greatly
reduced by taking the differences between the Test
and Control measurements
 The model above tests whether a significant change
has occurred by testing the significance of the
interaction term of the model for the before after
indicator variables and the control-intervention
indictor variable. For example if the coefficient for
intervention patients and after intervention duration
has lower insured costs that before the intervention
after adjusting for controls, then the intervention
has had a significant impact on costs.
 The random effects terms and random error term
are assumed to be uncorrelated in time.
 The control patient is generally selected to control
for all covariates. In this study this means that
control patients should be identical to the
intervention patient in terms of age, gender, SEIFA
index and major comorbidities.
 The samples are selected over time (therefore they
are time series rather than repeated measures made
at the same time). So it may seem unlikely that the
model errors will be independently distributed but
hospital costs are measured a month apart and this
should be enough to for the assumption of
independence to be valid.
 The assumption that all repeated measures have the
same variance is unlikely to be true. If the gamlss
package is used then this change in variance can be
accounted for. Although theoretically longitudinal
data structures can be modelled by random effects
in gamlss [40] but at present no computationally
feasible implementation for large sample sizes and
complex models exists.
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time is approximately linear. This assumption is
likely to be reasonable over the 5 year study period,
but is unlikely to be true for longer time periods.
These models will be fitted using the nlme package in
R [39].
A hypothetical scenario is modelled schematically in
Figure 5 below according to principles and assumptions
outlined above.
The BACI analysis will be carried out using the statis-
tical modelling package R [38]. The output will provide
an estimate of the correlation between Test and Control
data and will provide best fits, standard errors, t-values
and p-values for all model parameters before and after
the intervention.
In the schematic diagram above we would expect very
little difference between Test and Control patients in
either the slope or the intercept of the model prior to
the start of the intervention. The hypothetical model in
Figure 5 shows that the impact will result in a change of
the historical slope of the model before the intervention
for Test patients, representing a time dependent fall in
Mean Monthly MBS Costs, whilst there is no corre-
sponding change in the slope for Control patients after
the intervention.
Modelling of the available data will reveal underlying
time dependent trends associated with the ageing
process as well as the impact of the intervention and will
allow an estimate to be made of savings associated with
the impact of the intervention.Figure 5 Output of lme modelling of mean monthly MBS cost per pa
monthly data point is plotted as a box and whiskers plot representing dataPower calculations
The power of the tests in the linear mixed model is not easy
to compute. The power of a match paired t-test is estimated
assuming a correlation of ρ and a standard deviation of σ
for the differences in match scores, a decision boundary for
a test of size κ departure between the match scores, and no
autocorrelation with an effective sample size of 30.
The power calculations based on independent observa-
tions and the outcomes of the test are given in Table 6:
taking




The actual results may be much more complicated
than this because the differences between the outcome
variables may be auto correlated. This is particularly true
if the test patient and the matched control patient out-
come measures have different time series trends. Testing
of whether the matched differences are auto correlated
will be carried out when data becomes available but is
not expected to be a significant problem.
Discussion
There are many clinical benefits associated with remote
patient monitoring with a large range of chronic condi-
tions [9]. Some of the evidence for this includes an
increase in mean survival time in a sample of 387 dia-
betic patients who undertook daily monitoring of vital
signs [41], a significant improvement in glycemic con-
trol in diabetic patients who transmitted blood glucose
and blood pressure data to a telehealth nurse [42], atient for test and control. Patients based on hypothetical data. Each
for the 125 Test patients and 250 Control patients.
Table 6 Power calculations for some selected variables
Outcome measure all on the monthly scale Effective
sample size?
Assumed normal distribution Shift
amount (K)
SPower
PBS Total cost 30 Log(PBS Total cost+1) 1 1.00
MBS out of hospital costs 30 Log(MBS out of hospital costs+1) 1 1.00
MBS in hospital costs 30 Log(MBS in hospital costs+1) 1 0.84
Number of hospital admissions 30 Square root the number of hospital admissions 0.5 0.99
Number of GP visits during working hours 30 Square root of number of GP visits during working hours 0.5 0.89
Number of GP visits outside of working hours 30 Square root of number of GP visits outside of working hours 0.1 0.50
Total number of GP visits 30 Square root of total number of GP visits 1 0.97
Total number of either Specialist, Psychiatric,
Allied Health visits and Procedures
30 Square root of total number of either Specialist,
Psychiatric, Allied Health visits and Procedures
1 0.77
Total number of Laboratory tests 30 Square root of total number of Laboratory tests 1 0.97
Number of Laboratory 30 Square root of number of Laboratory 1 0.96
Tests Tests
The actual results may be much more complicated than this because the differences between the outcome variables may be auto correlated. This is particularly
true if the test patient and the matched control patient outcome measures have different time series trends. Testing of whether the matched differences are auto
correlated will be carried out when data becomes available but is not expected to be a significant problem.
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in respiratory patients who had oxygen saturation
measured by pulse oximetry and monitored daily
[43], a reduction in the number of hospital readmis-
sions in patients with angina [44], significant im-
provements in health related quality of life and a
decrease in mortality in COPD patients using home
monitoring [45], a 43% reduction in hospitalizations
and a 68% reduction in bed days of care in cardiac
patients who transmitted daily ECG and blood pres-
sure data [46] and a 50% reduction in the risk of
heart failure related readmission and 55% reduction
in cardiovascular mortality in chronic heart failure
patients monitored at home [8].
The evidence therefore appears overwhelming that
at home telemonitoring can deliver significant patient
health benefits at lower cost and with a high level of ac-
ceptance by patients and their carers. Deployment of
telehealth services however is far from widespread.
Broadly speaking telehealth services has been embraced
most enthusiastically in the US with uptake in Australia
and the rest of the western industrialised nations patchy,
tentative and on a small scale rarely proceeding past the
trial stage.
Outside of the USA, the United Kingdom has the most
evolved infrastructure and government policy framework
for supporting at home telemonitoring, and is now promot-
ing a Public-Private Partnership to deploy telehealth ser-
vices to three million chronically ill patients. In Australia,
Government has been preoccupied with the funding of
national eHealth infrastructure through the establishment
of the National eHealth Transition Authority (NeHTA)
[47], and with the development of the national PersonallyControlled Electronic Health Record (PCEHR) [48] which
is now being slowly deployed and is receiving limited
acceptance from clinicians.
Telehealth video consultations between specialists and
patients in Residential Care Facilities or remote area
community health services are now being funded through
the Medicare system and the Consumer Directed Care
Program [21] which is replacing the existing Federally
funded care packages known as Home and Community
Care Packages (HACC), Community Aged Care Packages
(CACP) and Extended Aged Care in the Home
(EACH), also has provision for the supply of at home
tele-monitoring services.
With these initiatives in place it is probable that
Australia, will begin to implement large scale at home
telemonitoring services over the next few years. How-
ever there are significant uncertainties and impediments
that need to be resolved before large scale deployment
of telehealth services will become routine. These include
the following;
 Concern over funding models. The National Health
Insurance system has historically funded provider –
patient clinical consultations. There are concerns
that telehealth services may lead to cost blowouts in
essentially uncapped federal and state healthcare
budgets.
 State and Federal Government cost shifting. In
Australia the Federal Government funds primary
care and aged care and the State Governments fund
hospital services. If the Federal Government funds
telehealth to reduce unnecessary hospitalisation of
those with chronic conditions, the primary beneficiaries
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alignment of those that pay and those that benefit!
 Limited awareness and support for telehealth services
among clinicians, service providers and patients.
 Varying levels of organisational readiness within
State Governments, local health districts and not for
profit health service providers for the deployment of
telehealth services.
 A lack of data on how to identify those patients that
would benefit most from at home telemonitoring for
their chronic conditions, and a robust process for
allocating tele monitoring resources throughout the
disease life cycle from early intervention for early
stage disease conditions such as Type II diabetes,
through to complex chronic conditions with
multiple co-morbidities such as CHF patients with
COPD and CHD.
 A robust process for selecting competitive at home
telemonitoring services that provide the best quality
patient data and opportunity for clinical diagnosis.
Ensuring that systems are inter operable and
standards based and can automatically transfer data
securely to either provider controlled or national
electronic health records.
The clinical trial design for this national trial was for-
mulated to provide statistically robust evidence, valid
across a number of existing healthcare settings in
Australia to inform Government policy and funding
frameworks as well as to provide a template for the
adoption of telehealth services by a range of private and
public healthcare service delivery organisations.Abbreviations
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